Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00028366
First received: December 27, 2001
Last updated: August 15, 2012
Last verified: August 2012